Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice

J G Christensen1, E H Romach, L N Healy

  • 1Chemical Industry Institute of Toxicology, Research Triangle Park, NC 27709, USA. james.christensen@wl.com

Carcinogenesis
|July 30, 1999
PubMed

Insights

Dysregulation of apoptosis, crucial in liver cancer, involves altered bcl-2 protein family expression. This study shows specific bcl-2 and bcl-X(L) changes during non-genotoxic mouse liver carcinogenesis.

Area of Science:

  • Hepatology
  • Cancer Biology
  • Molecular Toxicology

Background:

  • Apoptosis dysregulation is key in multistage hepatocarcinogenesis.
  • The bcl-2 protein family regulates apoptosis and is altered in various cancers.

Purpose of the Study:

  • To investigate bcl-2 protein family expression changes in mouse liver during acute and chronic non-genotoxic carcinogen exposure.
  • To correlate these changes with specific lesion types during hepatocarcinogenesis.

Main Methods:

  • Acute and chronic administration of non-genotoxic carcinogens (phenobarbital, WY-14,643, tetrachlorodibenzo-p-dioxin, chlordane) to B6C3F1 mice.
  • Immunohistochemical analysis of bcl-2, bax, BAG-1, and bcl-X(L) protein expression in liver foci, adenomas, and carcinomas.
  • Classification of lesions based on morphology and carcinogen treatment.

Main Results:

  • Acute treatment altered bcl-2, bax, and BAG-1 levels.
  • Specific lesion types showed distinct bcl-2 and bcl-X(L) expression patterns.
  • Increased bcl-2 was common in small-cell lesions, while bcl-X(L) predominated in acidophilic lesions.
  • Most carcinomas showed increased bcl-2 and/or bcl-X(L).

Conclusions:

  • Apoptotic protein regulation is altered during non-genotoxic mouse liver carcinogenesis.
  • Expression patterns of bcl-2 family proteins are both chemical- and lesion-specific during hepatocarcinogenesis.